Reply to: "Probability of HBsAg loss after nucleos(t)ide analogue withdrawal depends on HBV genotype and viral antigen levels"

J Hepatol. 2022 Oct;77(4):1224-1226. doi: 10.1016/j.jhep.2022.06.028. Epub 2022 Jul 8.

Authors

Milan J Sonneveld¹, Shao-Ming Chiu², Chien-Hung Chen², Benjamin Maasoumy³; CREATE study group

Affiliations

¹ Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands. Electronic address: [email protected].
² Department of Internal Medicine, Koahsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
³ Department of Gastroenterology and Hepatology, Hannover Medical School, Hannover, Germany.

PMID: 35810930
DOI: 10.1016/j.jhep.2022.06.028

No abstract available

Publication types

Letter
Comment

MeSH terms

Antiviral Agents / therapeutic use
DNA, Viral
Genotype
Hepatitis B Surface Antigens*
Hepatitis B e Antigens
Hepatitis B virus* / genetics
Nucleosides
Probability
Treatment Outcome

Substances

Antiviral Agents
DNA, Viral
Hepatitis B Surface Antigens
Hepatitis B e Antigens
Nucleosides